40 results on '"Filler, Guido"'
Search Results
2. Nephrotic state substantially enhances apparent mycophenolic acid clearance .
- Author
-
Kirpalani A, Rothfels L, Sharma AP, Cuellar CR, and Filler G
- Subjects
- Adolescent, Albuminuria urine, Child, Child, Preschool, Cholesterol blood, Drug Monitoring, Female, Glomerular Filtration Rate, Hematocrit, Humans, Immunosuppressive Agents blood, Infant, Kidney Transplantation, Male, Mycophenolic Acid blood, Retrospective Studies, Serum Albumin metabolism, Tandem Mass Spectrometry, Triglycerides blood, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents therapeutic use, Mycophenolic Acid pharmacokinetics, Mycophenolic Acid therapeutic use, Nephrotic Syndrome drug therapy
- Abstract
Background: ; Several factors may decrease plasma protein binding of mycophenolic acid (MPA), the active compound of mycophenolate mofetil (MMF), and potentially enhance its clearance. It is unclear if MMF dose adjustments are required for the treatment of steroid-resistant nephrotic syndrome (SRNS). Therapeutic drug monitoring of MPA levels is not widely utilized in the treatment of steroid-resistant nephrotic syndrome (SRNS)., Materials and Methods: In this retrospective cohort study, the authors measured 182 MPA predose trough levels (1 - 45/patient, HPLC/MS/MS) in 10 patients aged 0.9 - 18 years with SRNS treated with MMF. Apparent MPA clearances (CL/F) were calculated from the dose/estimated AUC. Anthropomorphic data, blood parameters, and proteinuria levels were collected from electronic health records. We compared all parameters with apparent MPA clearance, including albumin level, microalbuminuria, proteinuria, triglycerides, cystatin C, and estimated glomerular filtration rate (eGFR), analyzed by nonlinear regression analysis., Results: Median apparent clearance was 22.63 L/h (IQR 17.1, 32.47). Significant correlations were found between MPA Cl/F and serum albumin (r = -0.47), microalbuminuria (+0.54), triglycerides (+0.33), and cholesterol (+0.32). CL/F increased from a minimum of 2.4 L/h for the highest albumin levels to a maximum of 59.9 for albumin levels < 25 g/L. Similarly, the apparent MPA clearance increased significantly with higher triglycerides and lower hematocrit., Conclusion: This study confirms a significant increase of the apparent clearance of MPA with low serum albumin, microalbuminuria, proteinuria, high triglycerides, and low hematocrit. The 20-fold increase of the apparent clearance suggests that MMF unresponsiveness in the nephrotic state may be related to MPA underexposure. .
- Published
- 2019
- Full Text
- View/download PDF
3. Appreciating the need for greater understanding of the pharmacokinetics of drugs in children and adolescents.
- Author
-
Filler G and Bravo M
- Subjects
- Adolescent, Age Factors, Child, Child, Preschool, Delayed-Action Preparations, Genetic Variation, Humans, Infant, Infant, Newborn, Multicenter Studies as Topic, Tacrolimus pharmacokinetics, Time Factors, Clinical Trials as Topic, Immunosuppressive Agents pharmacokinetics, Pharmacogenetics
- Published
- 2018
- Full Text
- View/download PDF
4. Generic immunosuppressants.
- Author
-
Medeiros M, Lumini J, Stern N, Castañeda-Hernández G, and Filler G
- Subjects
- Cyclosporine pharmacokinetics, Cyclosporine standards, Cyclosporine therapeutic use, Drug Substitution standards, Drugs, Generic pharmacokinetics, Drugs, Generic standards, Graft Rejection immunology, Humans, Immunosuppression Therapy standards, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents standards, Mycophenolic Acid pharmacokinetics, Mycophenolic Acid standards, Mycophenolic Acid therapeutic use, Randomized Controlled Trials as Topic, Tacrolimus pharmacokinetics, Tacrolimus standards, Tacrolimus therapeutic use, Therapeutic Equivalency, Treatment Outcome, United States, United States Food and Drug Administration standards, Drugs, Generic therapeutic use, Graft Rejection prevention & control, Immunosuppression Therapy methods, Immunosuppressive Agents therapeutic use, Organ Transplantation adverse effects
- Abstract
Immunosuppressive drugs for solid organ transplantation are critical dose drugs with a narrow therapeutic index. Many of the most commonly used innovator drugs are off patent and have been replicated by generic counterparts, often at substantial cost-savings to the patient. However, serious adverse events caused by the transition from innovator to generic medications, specifically in pediatric solid organ transplant recipients, have questioned these autosubstitutions. The purpose of this review is to summarize the criteria set forth by the regulatory bodies, and to examine how major immunosuppressive drugs conform to these recommendations. Regulatory bodies have established inconsistent criteria to demonstrate bioequivalence between innovator and generic medications, causing approved generic variations to have varying levels of equivalence with the innovator drugs. In order to minimize the risk for under-immunosuppression, the following recommendations have been concluded. Brand prescribing of cyclosporine and tacrolimus are recommended due to evidence of adverse events after conversion to generic formulations and differences in dissolution parameters. Mycophenolate mofetil (MMF) shows better bioequivalence between innovator and generic formulations, however caution should be advised when switching between formulations. The institution of 'innovator only' policies may be appropriate at this time in order to minimize the risk of under-immunosuppressing patients until the evidence of more stringent bioequivalence has been established.
- Published
- 2018
- Full Text
- View/download PDF
5. A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA.
- Author
-
Alvarez-Elías AC, Yoo EC, Todorova EK, Singh RN, and Filler G
- Subjects
- Area Under Curve, Child, Child, Preschool, Drug Monitoring methods, Female, Glomerular Filtration Rate drug effects, Graft Rejection prevention & control, Humans, Kidney Transplantation methods, Male, Retrospective Studies, Drug Interactions physiology, Immunosuppressive Agents therapeutic use, Mycophenolic Acid therapeutic use, Prednisone therapeutic use, Sirolimus therapeutic use, Tacrolimus therapeutic use
- Abstract
Mycophenolic acid (MPA), the active compound of mycophenolate mofetil (MMF), is widely used as an antirejection drug after renal transplantation. There is growing evidence supporting the notion that there is substantial variability in the intra- and interpatient exposure to MPA. Drug interactions involving MPA with tacrolimus, steroids, and sirolimus have been understudied. The objective of this study was to determine the relationship between MPA, steroids, tacrolimus, and sirolimus. MPA trough concentrations from 37 pediatric renal transplant recipients (mean age 7.6 years at transplant) followed for a median follow-up of 7.8 years were analyzed retrospectively and 2131 dose-normalized MPA trough concentrations were evaluated against all known covariates including all concomitant immunosuppressant drug doses and exposure, age, albumin, hematocrit, and estimated glomerular filtration rate (eGFR). Age, hematocrit, and estimated glomerular filtration rate affected the dose-normalized MPA trough concentrations. The authors used appropriate linear regression univariate models and created 5 different multivariate models to examine individual drug-drug interactions (DDIs). Although the authors' findings support the notion that there is a DDI between MMF and both sirolimus and steroids, the sample size was small, and these findings should be confirmed in future studies. The authors found no DDIs between tacrolimus and MMF, the prodrug of MPA. These findings are important because there is a tendency to under-dose MMF early and to overdose late after transplantation. The DDI between sirolimus and MMF has not been described. Although therapeutic drug monitoring of MMF therapy is often not performed, the data presented here indicate a necessity for therapeutic drug monitoring. This is especially true when converting from tacrolimus to sirolimus, as a way to avoid MPA underexposure and organ rejection.
- Published
- 2017
- Full Text
- View/download PDF
6. Idiosyncratic drug reactions and membranous glomerulopathy.
- Author
-
Kirpalani A, Rieder MJ, Bax KC, and Filler G
- Subjects
- Cell Survival, Deprescriptions, Drug Substitution, Failure to Thrive chemically induced, Gingival Hyperplasia chemically induced, Glomerulonephritis, Membranous diagnosis, Glomerulonephritis, Membranous pathology, Humans, Hypertrichosis chemically induced, In Vitro Techniques, Infant, Kidney Glomerulus ultrastructure, Male, Microscopy, Electron, Muscle Weakness chemically induced, Serositis chemically induced, Cyclosporine adverse effects, Enteritis chemically induced, Eosinophilia chemically induced, Gastritis chemically induced, Glomerulonephritis, Membranous drug therapy, Immunosuppressive Agents adverse effects, Seizures chemically induced, Tacrolimus adverse effects, Vasculitis chemically induced
- Abstract
An infant boy with steroid-resistant nephrotic syndrome (idiopathic membranous glomerulonephropathy) achieved remission with ciclosporin but developed eosinophilia and high IgE levels (max 19 000 iU/mL). Conversion to tacrolimus resulted in chronic diarrhoea (eosinophilic gastroenteritis), muscle weakness, polyserositis and failure-to-thrive. In contrast, a trial without tacrolimus resulted in a ciclosporin-responsive relapse, therapy-resistant focal seizures with generalised spikes, worsening muscle weakness and diarrhoea. The patient was weaned off of ciclosporin and completely normalised. In vitro testing demonstrated decreased viability of the patient's cells when incubated with calcineurin inhibitors (ciclosporin, 70%; tacrolimus, 80% compared to control cells), supporting their role in this adverse drug reaction., Competing Interests: Competing interests: None declared., (2017 BMJ Publishing Group Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
7. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.
- Author
-
Filler G, Alvarez-Elías AC, McIntyre C, and Medeiros M
- Subjects
- Adolescent, Child, Graft Rejection immunology, Graft Rejection prevention & control, Humans, Immunosuppressive Agents pharmacokinetics, Mycophenolic Acid pharmacokinetics, Drug Monitoring, Immunosuppressive Agents therapeutic use, Kidney Transplantation methods, Mycophenolic Acid therapeutic use
- Abstract
We have reviewed current evidence on the therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) in relationship to drug efficacy and safety. The relationship between actual MPA exposure and mycophenolate mofetil (MMF) dose has been shown to be weak in children and adolescents. The TDM of MPA exposure should ideally be performed using full pharmacokinetic profiles or limited sampling strategies. Recent evidence has provided some rationale for using the post-dose trough level as a single measure. In terms of short-term efficacy, there is strong evidence that a MPA area under the time-concentration curve of >30 mg × h/L reduces acute rejection episodes early after renal transplantation, and there is evolving evidence that aiming for the same exposure over the long term may be a viable strategy to reduce the formation of donor-specific antibodies. Strong evidence also supports the existence of important drug interactions and age/developmental dependent differences in drug metabolism that may necessitate the need for TDM of MMF therapy. Based on these findings and given the substantial inter- and intra-patient variability of MPA exposure, it would appear that MMF therapy should be subject to TDM to avoid over- and under-dosing. This may be a viable strategy to reduce treatment-emergent adverse events and to increase the effective pediatric transplant survival rates.
- Published
- 2017
- Full Text
- View/download PDF
8. Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage?
- Author
-
Medeiros M, Valverde S, Del Moral I, Velásquez-Jones L, Hernández AM, Castañeda-Hernández G, Reyes H, and Filler G
- Subjects
- Adolescent, Area Under Curve, Child, Child, Preschool, Dose-Response Relationship, Drug, Female, Humans, Immunosuppressive Agents administration & dosage, Male, Nephrotic Syndrome physiopathology, Recurrence, Tacrolimus administration & dosage, Time Factors, Immunosuppressive Agents pharmacokinetics, Nephrotic Syndrome drug therapy, Tacrolimus pharmacokinetics
- Abstract
Background: Although tacrolimus therapy is not the first-line therapy for childhood nephrotic syndrome, it is often used instead of cyclosporine to ameliorate the side effects. The pharmacokinetics (PK) of tacrolimus (Tac) can be influenced by many conditions, and it has a high plasma protein binding. The Tac PK during relapse and remission of childhood nephrotic syndrome has not been well described., Methods: We performed 14 PK profiles (with measurements before intake and 0.5, 1, 2, 4, and 12 hours postintake) in 7 children with steroid-resistant nephrotic syndrome at week 1 (all nephrotic) and week 16 after Tac therapy (all in remission). These data were compared with historical PK data of 161 PK profiles in 87 pediatric renal transplant recipients with measurements before intake and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postintake. Tac levels were measured using the Abbott Tacro II assay. We used descriptive statistics to generate percentiles and compared these with those of patients with steroid-resistant nephrotic syndrome., Results: The median age of patients with nephrotic syndrome was 3.2 years (range 2.5, 17.2), male gender 71.4%, significantly younger than the control group. Median Tac dose was similar during both PK profiles (0.11 mg·kg·d at week 1 versus 0.13 mg·kg·d at week 16, P = 0.81). There were no statistically significant differences in median dose-normalized area-under-the-time-concentration profiles, peak concentration, time to reach peak concentration, and Tac trough levels. Individual dose-normalized Tac levels for each time point during the PK profile were also not different (P = 0.81)., Conclusions: We conclude that Tac PK profiles are unaltered during relapse of nephrotic syndrome.
- Published
- 2016
- Full Text
- View/download PDF
9. What is the intrapatient variability of mycophenolic acid trough levels?
- Author
-
Todorova EK, Huang SH, Kobrzynski MC, and Filler G
- Subjects
- Adolescent, Area Under Curve, Biomarkers blood, Child, Child, Preschool, Drug Monitoring, Follow-Up Studies, Humans, Immunosuppressive Agents therapeutic use, Mycophenolic Acid pharmacokinetics, Mycophenolic Acid therapeutic use, Retrospective Studies, Graft Rejection prevention & control, Immunosuppressive Agents pharmacokinetics, Kidney Transplantation, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid blood
- Abstract
TDM of MPA, the active compound of MMF, is rarely used despite its substantial intra- and interpatient variability. Little is known about the utility of long-term MPA TDM. Data are expressed as mean (one standard deviation). All available data from 27 renal transplant recipients (mean age at transplantation: 7.7 [5.0] yr) with an average follow-up of 9.3 (4.6) yr were analyzed. MPA levels were measured using the EMIT. GFR was measured using cystatin C and eGFR was calculated using the Filler formula. Intrapatient CV of the trough level was calculated as the ratio of the mean divided by one standard deviation. Mean cystatin C eGFR was 56.9 (24.4) mL/min/1.73 m(2) . There was a weak but significant correlation between the MPA trough level and the AUC (Spearman r = 0.6592, p < 0.0001). A total of 1964 MPA trough levels (73 [45]/patient) were measured, as compared to 3462 Tac trough levels (144 [71]/patient). The average MPA trough level was 3.01 (1.26) mg/L and the average trough Tac level was 7.3 (1.8) ng/mL. Intrapatient CV was statistically higher (p = 0.00093) for MPA at 0.68 (0.29) when compared to Tac with a CV of 0.46 (0.12). CV did not correlate with eGFR. Intrapatient MPA trough level CV is significantly higher than for Tac, while CV for both MPA and Tac was high. MPA trough level monitoring may be a feasible monitoring option to improve patient exposure and possibly outcomes., (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
10. The need for tacrolimus assay standardization.
- Author
-
Filler G and Smith N
- Subjects
- Animals, Drug Stability, Humans, Reference Standards, Immunosuppressive Agents standards, Tacrolimus standards
- Published
- 2014
- Full Text
- View/download PDF
11. Finding the optimal therapeutic window for tacrolimus.
- Author
-
Filler G
- Subjects
- Female, Humans, Male, Drug Monitoring, Graft Rejection prevention & control, Immunosuppressive Agents blood, Kidney Transplantation, Tacrolimus blood
- Published
- 2014
- Full Text
- View/download PDF
12. Rapid resolution of tacrolimus intoxication-induced AKI with a corticosteroid and phenytoin.
- Author
-
Bax K, Tijssen J, Rieder MJ, and Filler G
- Subjects
- Child, Drug Therapy, Combination, Female, Humans, Kidney Transplantation, Glucocorticoids therapeutic use, Immunosuppressive Agents adverse effects, Methylprednisolone therapeutic use, Phenytoin therapeutic use, Tacrolimus adverse effects
- Abstract
Objective: To report a novel approach to the management of tacrolimus intoxication that leads to rapid normalization of serum tacrolimus concentrations., Case Summary: A 9-year-old female renal transplant recipient developed a severe tacrolimus intoxication as a result of prolonged diarrhea, which resulted in acute kidney injury, severe dehydration, and neurological symptoms. We used a combination of intravenous steroids and intravenous phenytoin to normalize the tacrolimus level from 32 to 5 ng/mL in less than 24 hours, with complete resolution of symptoms and signs., Discussion: Tacrolimus intoxication is a rare event but may result in life-threatening complications. Treatment recommendations beyond holding the drug and enzyme induction with phenytoin or phenobarbital are elusive. This approach leads to a relatively slow normalization of the tacrolimus level over 72 hours. The authors hypothesized that additional induction of the p-glycoprotein through steroids was synergistic., Conclusions: The combination of phenytoin and a corticosteroid may be an effective approach that leads to rapid normalization of severely elevated tacrolimus levels., (© The Author(s) 2014.)
- Published
- 2014
- Full Text
- View/download PDF
13. The problem with generic immunosuppressants.
- Author
-
Filler G and Kobrzyński M
- Subjects
- Drug Approval, Drug Costs, Drugs, Generic chemistry, Drugs, Generic economics, Humans, Immunosuppressive Agents chemistry, Immunosuppressive Agents economics, Licensure, Mycophenolic Acid chemistry, Mycophenolic Acid economics, Prodrugs chemistry, Prodrugs pharmacology, Therapeutic Equivalency, United States, United States Food and Drug Administration, Drugs, Generic pharmacology, Immunosuppressive Agents pharmacology, Mycophenolic Acid pharmacology
- Published
- 2014
- Full Text
- View/download PDF
14. Similar MPA exposure on modified release and regular tacrolimus.
- Author
-
Filler G, Vinks AA, Huang SH, Jevnikar A, and Muirhead N
- Subjects
- Adult, Aged, Area Under Curve, Cross-Over Studies, Delayed-Action Preparations, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Mycophenolic Acid pharmacokinetics, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents pharmacology, Kidney Transplantation, Mycophenolic Acid analogs & derivatives, Tacrolimus administration & dosage, Tacrolimus pharmacology
- Abstract
Concomitant immunosuppression may affect the mycophenolate mofetil exposure. Astellas developed a once-daily modified release formulation of tacrolimus (TacMR) with the potential to reduce the likelihood of nonadherence. It is unknown whether mycophenolic acid (MPA) area under the concentration-time curve (AUC) differs between the 2 tacrolimus (Tac) formulations. In a 2-by-2 crossover design, 20 stable renal transplant recipients on twice-daily Tac either continued their usual Tac therapy (n = 10, group 1) or switched to TacMR for a 12-week period (n = 10, group 2), after which the patients crossed over to the other formulation for another 12-week period. Pharmacokinetic profiles using limited sampling strategies were obtained before randomization (visit 1), and at 12 (visit 2) and 24 weeks (visit 3) at steady state. MPA AUC was calculated using the Pawinski formula. When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109). We conclude that MPA pharmacokinetic profiles are not altered when converting patients from Tac to TacMR.
- Published
- 2014
- Full Text
- View/download PDF
15. Do we need to worry about mycophenolate overdose?
- Author
-
Filler G and Ferrand A
- Subjects
- Female, Humans, Male, Mycophenolic Acid adverse effects, Drug Overdose therapy, Immunosuppressive Agents adverse effects, Mycophenolic Acid analogs & derivatives
- Abstract
Introduction: To discuss the significance of the recent observational case series from the Swiss Toxicological Information Centre (STIC). Mycophenolic acid (MPA) and its prodrug mycophenolate mofetil are immunosuppressive agents that are frequently prescribed in renal transplant recipients, and their safety profiles must be established., Areas Covered: This case series and systemic literature analysis consists of 15 cases of MPA overdose from the STIC and a systemic analysis of the literature over the past 18 years. This study focuses on acute overdosing, the effects of which are presumably mild. In contrast, the effects of long-term overdosing may be much more severe. Substantial underreporting is likely. The pharmacokinetic monitoring of MPA is rarely performed, which is both striking and does not coincide with findings in academic literature. The scant data on pharmacokinetic monitoring presented demonstrated that MPA has a short terminal half-life, which suggests that decontamination and activated charcoal treatment in acute overdose may not be necessary., Expert Opinion: The case series and systematic literature analysis of acute mycophenolate overdose represent an important contribution toward increasing the safety of MPA therapy.
- Published
- 2014
- Full Text
- View/download PDF
16. Should we consider MMF therapy after rituximab for nephrotic syndrome?
- Author
-
Filler G, Huang SH, and Sharma AP
- Subjects
- Female, Humans, Male, Mycophenolic Acid therapeutic use, Rituximab, Antibodies, Monoclonal, Murine-Derived therapeutic use, Immunosuppressive Agents therapeutic use, Mycophenolic Acid analogs & derivatives, Nephrotic Syndrome drug therapy
- Abstract
The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.
- Published
- 2011
- Full Text
- View/download PDF
17. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
- Author
-
Tönshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, Kuypers DR, Tsai E, Vinks AA, Weber LT, and Zimmerhackl LB
- Subjects
- Child, Humans, Drug Monitoring methods, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Kidney Transplantation, Mycophenolic Acid therapeutic use
- Abstract
Mycophenolate mofetil (MMF) is widely used for maintenance immunosuppressive therapy in pediatric renal and heart transplant recipients. Children undergo developmental changes (ontogeny) of drug disposition, which may affect drug metabolism of the active compound mycophenolic acid (MPA). Therefore, a detailed characterization of MPA pharmacokinetics and pharmacodynamics in this patient population is required. In general, the overall efficacy and tolerability of MMF in pediatric patients appear to be comparable with those in adults, except for a higher prevalence of gastrointestinal adverse effects in children younger than 6 years. The currently recommended dose in pediatric patients with concomitant cyclosporine is 1200 mg/m(2) per day in 2 divided doses; the recommended MMF dose with concomitant tacrolimus or without a concurrent calcineurin inhibitor is 900 mg/m(2) per day in 2 divided doses. Recent data suggest that fixed MMF dosing results in MPA underexposure (MPA-area under the concentration-time curve (AUC(0-12)), <30 mg × h/L) early posttransplant in approximately 60% of patients. To achieve adequate MPA exposure in most patients, an initial MMF dose of 1800 mg/m(2) per day with concomitant cyclosporine and 1200 mg/m(2) per day with concomitant tacrolimus for the first 2 to 4 weeks posttransplant has been suggested. As in adults, there is an approximately 10-fold variability in dose-normalized MPA-AUC(0-12) values between pediatric patients after renal transplantation, strengthening the argument for concentration-controlled dosing of the drug. Although the clinical utility of therapeutic drug monitoring of MPA for graft outcome and patient survival is still controversial, potential indications are the avoidance of underimmunosuppression, particularly in patients with high immunologic risk in the initial period posttransplant, in patients who are treated with protocols that explore the possibilities of calcineurin inhibitor minimization, withdrawal or even complete avoidance, and steroid withdrawal or avoidance regimens that might also benefit from intensified therapeutic drug monitoring of MPA. An additional indication especially in adolescent patients is the monitoring of drug adherence. Therapeutic drug monitoring of MPA in pediatric solid organ transplantation using limited sampling strategies is preferable over drug dosing based on trough level monitoring only. Several validated pediatric limited sampling strategies are available. Clearly, more research is required to determine whether pediatric patients will benefit from therapeutic drug monitoring of MPA for long-term maintenance immunosuppression with MMF., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
18. Progress in pediatric kidney transplantation.
- Author
-
Filler G and Huang SH
- Subjects
- Humans, Hypertension prevention & control, Immunosuppression Therapy, Kidney Failure, Chronic, Reperfusion Injury, Child, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Kidney Transplantation immunology, Mycophenolic Acid therapeutic use
- Abstract
This review summarizes the focus shift from ischemia-reperfusion injury and avoidance of rejection to long-term outcome after pediatric renal transplantation over the past decade. Although there has been excellent 1-year graft and patient survival, low rejection rates can be achieved with modern immunosuppression after pediatric renal transplantation, and patient survival is improved substantially in comparison with dialysis, pediatric renal transplant recipients experience a high prevalence of infections, malignancies, medication side effects, nonadherence, and, most importantly, cardiovascular morbidity and mortality. Additional challenges occur because of a high prevalence of obesity after transplantation and vascular calcifications. There is also in an underappreciation of chronic kidney disease (CKD) in transplant recipients. The etiology of CKD is multifactorial and can affect graft and patient survival. The rigors of treatment for CKD are less compared with CKD in nontransplant recipients. Almost all immunosuppressive drugs are implicated with a risk of hypertension, hyperlipidemia, and diabetogenicity, all of which contribute to cardiovascular morbidity. Corticosteroids exhibit the most substantial risk and also stunt growth. Effective new treatment protocols such as the recent European Tacrolimus and WIthdrawal of STeroids (TWIST) study with rapid steroid withdrawal after 5 days provide promising results without increasing the rejection risk. The shift in focus on long-term complications allows for improved graft outcome. Side effects of immunosuppressive medications require continued attention to further improve long-term outcomes.
- Published
- 2010
- Full Text
- View/download PDF
19. Limited sampling strategies for sirolimus after pediatric renal transplantation.
- Author
-
Forbes N, Schachter AD, Yasin A, Sharma AP, and Filler G
- Subjects
- Area Under Curve, Child, Chromatography, High Pressure Liquid, Humans, Immunosuppressive Agents administration & dosage, Linear Models, Retrospective Studies, Sirolimus administration & dosage, Immunosuppressive Agents pharmacokinetics, Kidney Transplantation, Sirolimus pharmacokinetics
- Abstract
SRL has been increasingly used in renal transplantation, but limited sampling approaches for estimation of AUC remain elusive. A post-hoc analysis of 94 PK profiles in 75 patients from four previous studies was performed to generate limited sampling approaches for approximation of AUC based on two to four time points for both BID and OD SRL dosing. AUC was calculated using the trapezoid rule. Stepwise linear regression was performed to generate an abbreviated AUC from the limited sampling approaches. For BID dosing, complete AUC had a strong correlation with the trough levels (r(2) = 0.882, p < 0.0001) and with C2 level (r(2) = 0.9025, p < 0.0001). A three-point and a four-point limited sampling approach showed improved agreement with complete AUC compared with single-point sampling. A convenient and accurate (r(2) = 0.992) four-point limited sampling approach reads: AUC = 10;(1.085 + 0.117 x log C0 + 0.164 x log C1-0.131 x log C2 + 0.823 x log C4). Similarly, complete AUC had a statistically significant correlation with the trough levels (r(2) = 0.549, p < 0.0001) and with C2 level (r(2) = 0.716, p < 0.0001) for OD dosing. The estimation of AUC for OD dosing was improved over single-point sampling (r(2) = 0.951) using the formula: AUC = 10;(1.100 + 0.115 x log C0 + 0.803 x log C4). This study represented the first limited sampling approach for SRL. Further studies are required to determine the optimal SRL target AUC.
- Published
- 2009
- Full Text
- View/download PDF
20. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients.
- Author
-
Filler G, Bendrick-Peart J, Strom T, Zhang YL, Johnson G, and Christians U
- Subjects
- Area Under Curve, Child, Chromatography, High Pressure Liquid, Chromatography, Liquid, Female, Humans, Immunosuppressive Agents chemistry, Immunosuppressive Agents metabolism, Male, Sirolimus chemistry, Sirolimus metabolism, Tandem Mass Spectrometry, Immunosuppressive Agents pharmacokinetics, Kidney Transplantation physiology, Liver Transplantation physiology, Sirolimus pharmacokinetics
- Abstract
Potential age-dependent changes of sirolimus metabolite patterns in pediatric renal transplant recipients remain elusive. Thirteen pediatric solid organ transplant recipients (10 kidney, one combined liver-kidney, two liver, mean age 8.0 +/- 5.0 yr) underwent a sirolimus pharmacokinetic profile in steady-state with 10 samples drawn over 12 h post-intake to calculate the AUC(0-12 h). Concentrations of sirolimus and metabolite were quantified using a validated LC-MS/MS assay and metabolite structures were identified directly in blood extracts using LC-MS/iontrap. Average sirolimus AUC(0-12 h) was 64.9 +/- 29.7 ng h/mL. Median (range) AUC(0-12 h) for each metabolite (ng h/mL) was: 12-hydroxy-sirolimus 7.6 (0.2-18.8), 46-hydroxy sirolimus 3.1 (0.0-12.4), 24-hydroxy sirolimus 4.3 (0.0-12.6), piperidine-hydroxy sirolimus 3.5 (0.0-8.3), 39-O-desmethyl sirolimus 3.6 (0.0-11.3), 16-O-desmethyl sirolimus 5.0 (0.1-9.9), and di-hydroxy sirolimus 4.3 (0.0-32.5). The metabolites reached a median total AUC(0-12 h) of 60% of that of sirolimus. The range was 2.6-136%, indicating significant variability. In all, 77.5% of the metabolites were hydroxylated, while 39-O-desmethyl sirolimus accounted for only 8.4% of the AUC(0-12 h). This is clinically relevant as 39-O-desmethyl sirolimus shows 86-127% cross-reactivity with the antibody of the widely used Abbott sirolimus immunoassay. The metabolism of sirolimus in the children included in our study differed from that reported in adults, which should be considered when monitoring sirolimus exposure immunologically.
- Published
- 2009
- Full Text
- View/download PDF
21. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.
- Author
-
Sharma AP and Filler G
- Subjects
- Antibodies, Monoclonal, Murine-Derived, Drug Therapy, Combination, Humans, Infant, Mycophenolic Acid administration & dosage, Nephrotic Syndrome immunology, Remission Induction, Rituximab, Antibodies, Monoclonal administration & dosage, Immunologic Factors administration & dosage, Immunosuppressive Agents administration & dosage, Mycophenolic Acid analogs & derivatives, Nephrotic Syndrome drug therapy
- Published
- 2009
- Full Text
- View/download PDF
22. Pharmacokinetics of mycophenolate mofetil and sirolimus in children.
- Author
-
Filler G, Bendrick-Peart J, and Christians U
- Subjects
- Adolescent, Age Factors, Area Under Curve, Child, Cyclosporine administration & dosage, Cyclosporine metabolism, Cyclosporine pharmacokinetics, Dose-Response Relationship, Drug, Drug Interactions, Drug Therapy, Combination, Half-Life, Humans, Metabolic Clearance Rate, Mycophenolic Acid administration & dosage, Mycophenolic Acid metabolism, Mycophenolic Acid pharmacokinetics, Tacrolimus administration & dosage, Tacrolimus metabolism, Tacrolimus pharmacokinetics, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents metabolism, Immunosuppressive Agents pharmacokinetics, Mycophenolic Acid analogs & derivatives, Sirolimus administration & dosage, Sirolimus metabolism, Sirolimus pharmacokinetics
- Abstract
This review summarizes the pharmacokinetics in children and youths of 2 commonly used immunosuppressive drugs, mycophenolate mofetil (MMF) and sirolimus (Sir), as presented at the IATDMCT 2007 conference. The review focuses on the developmental changes of drug disposition during childhood and adolescence. Regarding mycophenolate mofetil, the authors were unable to demonstrate age dependency of MMF in combination with cyclosporine. By contrast, there was an inverse relationship between age and the dose-normalized mycophenolate (MPA) area-under-the-time-concentration curve (AUC) in children who received concomitant tacrolimus (Tac). Dose-normalized MPA AUCs were higher than commonly observed in adult patients. It can be hypothesized that the age dependency is related to developmental changes in the expression of the UDP-glucuronosyltransferases. Sirolimus half-life and mean residence time (MRT) are shorter than in adults. Similar to that in adults, there is a profound drug-drug interaction between cyclosporine and Sir. In our own experience, Sir was started at 0.13 +/- 0.05 mg/kg/day. The average Sir AUC was 64.9 +/- 29.7 ng*h/mL. The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL. Of the total metabolite AUC, 77.5% was due to hydroxylated metabolites, while 39-O-desmethyl Sir (the main metabolite in adults) comprised only 8.4% of the metabolites. This is clinically relevant, as 39-O-desmethyl Sir shows 86% to 127% cross-reactivity with the Sir immunoassay. Metabolites reached a median AUC of 60% of that of Sir, but the range was 2.6% to 136%. The age dependency of Sir metabolite formation was confirmed in a human liver microsome model. On the basis of the age dependency of piperidine-hydroxy Sir, the authors postulate that the ontogeny of the drug disposition can be largely explained by developmental changes of the CYP2C8 expression. In conclusion, both Sir and MMF drug disposition vary in children and adolescents from adult patients, most likely because of developmental changes of biliary transporters and metabolic enzymes.
- Published
- 2008
- Full Text
- View/download PDF
23. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.
- Author
-
Suri M, Tran K, Sharma AP, Filler G, and Grimmer J
- Subjects
- Antibodies, Monoclonal, Murine-Derived, Humans, Infant, Male, Nephrotic Syndrome etiology, Remission Induction, Rituximab, Steroids therapeutic use, Antibodies, Monoclonal therapeutic use, Glomerulosclerosis, Focal Segmental complications, Immunosuppressive Agents therapeutic use, Nephrotic Syndrome drug therapy
- Abstract
Background: Therapeutic options are limited in cases of focal and segmental glomerulosclerosis (FSGS) that fail to respond to steroids and calcineurin inhibitors. We describe a case in which steroid-resistant nephrotic syndrome (SRNS) secondary to FSGS did not respond to conventional treatment, but was successfully treated with rituximab. Unlike previous reports in which rituximab was used in conjunction with a calcineurin inhibitor, we present the first case where rituximab was used as the sole therapeutic agent., Case Report: An 11-month-old boy presented with severe manifestations of primary nephrotic syndrome with a subsequent non-responsive steroid course. A renal biopsy confirmed FSGS, with normal staining for podocin and nephrin. Genetic studies for podocin were normal. The child developed ciclosporin-induced hemolytic uremic syndrome (HUS), and the response to plasma exchange, following ciclosporin withdrawal, was only temporary. A trial of a combination of mycophenolate and dexamethasone did not have any effect on proteinuria or fluid status. Four weekly rituximab infusions at 375 mg/m2/dose induced a complete remission without any adverse effects., Conclusions: This case suggests that rituximab may be used as the sole therapeutic agent in the treatment of SRNS secondary to FSGS, especially in cases where calcineurin inhibitors are contraindicated.
- Published
- 2008
- Full Text
- View/download PDF
24. Sirolimus is not always responsible for new-onset proteinuria after conversion for chronic allograft nephropathy.
- Author
-
Abdurrahman Z, Sarwal M, Millan M, Robertson S, and Filler G
- Subjects
- Biopsy, Child, Chronic Disease, HLA Antigens, Humans, Immunosuppressive Agents therapeutic use, Liver Transplantation immunology, Male, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid therapeutic use, Immunosuppressive Agents adverse effects, Kidney Transplantation immunology, Kidney Transplantation pathology, Proteinuria etiology, Sirolimus adverse effects
- Abstract
An eight-yr-old combined liver and kidney transplant recipient for hyperoxaluria type I developed significant proteinuria and hypertension after conversion of a Tacrolimus, MMF, and corticosteroids-based immunosuppression to Sirolimus, low-dose Tacrolimus, and corticosteroids six and a half yr after the transplant for chronic allograft nephropathy. There was only one class I HLA match and the recipient had multiple blood exposures prior to transplantation. The patient was treated with combined hemodialysis and peritoneal dialysis while awaiting transplantation to reduce the oxalate load. A renal biopsy revealed a de novo transplant glomerulopathy that was associated with specific HLA antibodies unrelated to the donor (HLA DR 17 and 18). After reintroduction of MMF, these antibodies became undetectable and the proteinuria completely resolved. We hypothesize that HLA antibodies may cause transplant glomerulopathy even if they are not donor-specific. Their production appears more susceptible to MMF therapy. A thorough work-up of new-onset proteinuria after conversion to Sirolimus should be performed, including an immunological work-up and a renal biopsy.
- Published
- 2007
- Full Text
- View/download PDF
25. Calcineurin inhibitors in pediatric renal transplant recipients.
- Author
-
Filler G
- Subjects
- Child, Cyclosporine adverse effects, Cyclosporine pharmacokinetics, Cyclosporine pharmacology, Graft Rejection metabolism, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents pharmacology, Randomized Controlled Trials as Topic, Tacrolimus adverse effects, Tacrolimus pharmacokinetics, Tacrolimus pharmacology, Calcineurin Inhibitors, Cyclosporine therapeutic use, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Kidney Transplantation, Tacrolimus therapeutic use
- Abstract
The calcineurin inhibitors, cyclosporine (ciclosporin) [microemulsion] and tacrolimus, are the principal immunosuppressants prescribed for adult and pediatric renal transplantation. For pediatric patients, both drugs should be dosed per body surface area, and pharmacokinetic monitoring is mandatory. While monitoring of the trough levels may suffice for tacrolimus, cyclosporine therapy that utilizes the microemulsion formulation requires additional monitoring (e.g. determination of 2-hour post-dose levels). In a well designed randomized study in children, as in studies in adults, there was no difference in short-term patient and graft survival with cyclosporine microemulsion and tacrolimus. However, tacrolimus was significantly more effective than cyclosporine microemulsion in preventing acute rejection after renal transplantation when used in conjunction with azathioprine and corticosteroids. With regard to long-term outcome, the difference in acute rejection episodes resulted in a better glomerular filtration rate at 1 year after transplantation and eventually in better graft survival 4 years after renal transplantation. Whether this difference persists when calcineurin inhibitors are used in combination with mycophenolate mofetil has not been determined. The prevalence of hypomagnesemia was higher in the tacrolimus group whereas hypertrichosis and gingival hyperplasia occurred more frequently in the cyclosporine group. In contrast with adults, the incidence of post-transplantation diabetes mellitus was not significantly different between tacrolimus- and cyclosporine-treated patients. There was also no difference with regard to post-transplantation lymphoproliferative disorder. Medication costs were similar, but in view of the lower rejection episodes and better long-term graft survival as well as the more favorable cosmetic side effect profile, tacrolimus may be preferable. The recommendation drawn from the available data is that both cyclosporine and tacrolimus can be used safely and effectively in children. We recommend that cyclosporine should be chosen when patients experience tacrolimus-related adverse events.
- Published
- 2007
- Full Text
- View/download PDF
26. Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same!
- Author
-
Filler G, de Barros VR, Jagger JE, and Christians U
- Subjects
- Adolescent, Area Under Curve, Child, Dose-Response Relationship, Drug, Female, Humans, Male, Retrospective Studies, Cyclosporine administration & dosage, Cyclosporine pharmacokinetics, Glomerulosclerosis, Focal Segmental drug therapy, Heart Transplantation, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents pharmacokinetics, Kidney Transplantation
- Abstract
Not infrequently, physicians elect to divide CyA-ME from b.i.d. to t.i.d. dosing in an effort to minimize toxicity. Equivalent exposure is assumed. Few studies have compared 24-h PK profiles on both dosing regimes in the same patient. We retrospectively studied a heterogeneous population of seven pediatric patients (one heart transplant, five renal transplants and one FSGS patient) on both dosing regimes who had complete 24-h PK profiles on CyA-ME. Four patients were converted from b.i.d. to t.i.d. and three patients from t.i.d. to b.i.d. dosing. There was no difference in the dose/kg (5.66 +/- 2.52 mg/kg on b.i.d. dosing and 5.75 +/- 1.81 mg/kg on t.i.d. dosing, p = 0.8578, two-sided t-test). When comparing the dose-normalized AUCs over 24 h, every single patient demonstrated lower CyA-ME exposure on t.i.d. than on b.i.d. dosing with an average relative bioavailability that was 37.9% lower on t.i.d. than on b.i.d. dosing. The median dose-normalized AUC(0-->24h) dropped from 1620 ng x h x kg/mL x mg (range: 1253-4319) on b.i.d. to 1016 ng x h x kg/mL x mg (range: 712-1485, p = 0.02, Wilcoxon's matched pairs test) on t.i.d. dosing. Our results indicate t.i.d. dosing of CyA-ME results in significantly lower exposure when the same total dose is administered in two divided doses. This reduced exposure may potentially increase the risk for rejection.
- Published
- 2006
- Full Text
- View/download PDF
27. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
- Author
-
Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, Grenda R, Vondrak K, Hughes D, Offner G, Griebel M, Brekke IB, McGraw M, Balzar E, Friman S, and Trompeter R
- Subjects
- Adolescent, Adrenal Cortex Hormones therapeutic use, Azathioprine therapeutic use, Child, Emulsions, Europe, Female, Glomerular Filtration Rate, Graft Rejection epidemiology, Graft Survival, Humans, Incidence, Kidney Function Tests, Male, Prospective Studies, Cyclosporine therapeutic use, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Kidney Transplantation, Tacrolimus therapeutic use
- Abstract
This study was undertaken to compare the efficacy and safety of tacrolimus (Tac) with cyclosporin microemulsion (CyA) in pediatric renal recipients. A 6-month, randomized, prospective, open, parallel group study with an open extension phase was conducted in 18 centers from nine European countries. In total, 196 pediatric patients (<18 yr) were randomly assigned (1:1) to receive either Tac (n = 103) or CyA (n = 93) administered concomitantly with azathioprine and corticosteroids. The primary endpoint was incidence and time to first acute rejection (intent-to-treat). Baseline characteristics were comparable between treatment groups. Excluding deceased patients (n = 9) and patients lost to follow-up (n = 31, mostly transferred to adult care), 95% of 2-yr data (159 of 167 possible patients), 87% of 3-yr data (142 of 163) and 73% of 4-yr data (114 of 156) were retrieved. At 1 yr Tac therapy resulted in a significantly lower incidence of acute rejection (36.9%) compared with CyA (59.1%, p = 0.003). The incidence of corticosteroid-resistant rejection was also significantly lower with Tac (7.8% vs. 25.8%, p = 0.001). At 4 yr, patient survival was similar (94% vs. 92%, p = 0.86) but graft survival significantly favored Tac (86% vs. 69%; p = 0.025, log-rank test), respectively. At 1 yr, the mean glomerular filtration rate (GFR) (Schwartz formula, ml/min/1.73 m(2)) was 64.9 +/- 20.7 (n = 84) vs. 57.8 +/- 21.9 (n = 77, p = 0.0355), at 2 yr 64.9 +/- 19.8 (n = 71) vs. 51.7 +/- 20.3 (n = 66, p = 0.0002), at 3 yr 66.7 +/- 26.4 (n = 81) vs. 53.0 +/- 23.3 (n = 55, p = 0.0022), and at 4 yr 71.5 +/- 22.9 (n = 51) vs. 53.0 +/- 21.6 (n = 44, p = 0.0001) for Tac vs. CyA, respectively. Cholesterol remained significantly higher with CyA throughout follow-up. Three patients in each arm developed post-transplant lymphoproliferative disease. Incidence of insulin-dependent diabetes mellitus was not different. Tac was significantly more effective than CyA in preventing acute rejection in pediatric renal recipients. Renal function and graft survival were also superior with Tac. Glomerular filtration rate appears to be an useful surrogate marker for long-term outcome.
- Published
- 2005
- Full Text
- View/download PDF
28. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure.
- Author
-
Filler G, Womiloju T, Feber J, Lepage N, and Christians U
- Subjects
- Adolescent, Child, Child, Preschool, Drug Interactions, Drug Therapy, Combination, Female, Graft Rejection blood, Humans, Immunosuppressive Agents pharmacokinetics, Infant, Kidney Failure, Chronic blood, Kidney Failure, Chronic surgery, Male, Retrospective Studies, Sirolimus pharmacokinetics, Tacrolimus pharmacokinetics, Transplantation, Homologous, Graft Rejection drug therapy, Immunosuppressive Agents therapeutic use, Kidney Transplantation, Sirolimus therapeutic use, Tacrolimus therapeutic use
- Abstract
In adult renal recipients, coadministration of tacrolimus (TAC) and sirolimus (SIR) results in reduced exposure to TAC at SIR doses of 2 mg/day. Eight pediatric renal recipients (median age at transplant 2.0 years, range: 1.2-12.9 years) were converted to TAC- and SIR-based immunosuppression as a rescue therapy. All patients had biopsy-proven chronic allograft nephropathy. TAC levels were measured using a commercially available EMIT assay and SIR levels with a newly developed assay based on the LC-MS MS technology. SIR was started at 0.13+/-0.05 mg/kg/day (3.51+/-1.26 mg/m2/day) in two divided doses. TAC was given at 0.14+/-0.09 mg/kg/day, resulting in a trough level of 6.3+/-2.5 ng/mL. After the addition of SIR, the median dose required to keep TAC blood trough concentrations within the target range increased by 71.2% (range: 21.9-245.4%), dose-normalized TAC exposure (AUC) decreased to 67.1% and the dose-normalized C(max), a surrogate for absorption rate, to 53.8% (both geometric means) while terminal half-life (t1/2), a pharmacokinetic parameter characterizing systemic elimination, remained unchanged (p<0.93). Adding SIR to TAC-based immunosuppression in young pediatric renal transplant recipients results in a significant decrease of TAC exposure. TAC trough levels should be monitored frequently.
- Published
- 2005
- Full Text
- View/download PDF
29. How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored?
- Author
-
Filler G
- Subjects
- Adolescent, Area Under Curve, Child, Cyclosporine administration & dosage, Cyclosporine blood, Cyclosporine therapeutic use, Female, Humans, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents blood, Immunosuppressive Agents therapeutic use, Male, Monitoring, Physiologic, Cyclosporine pharmacokinetics, Immunosuppressive Agents pharmacokinetics, Nephrotic Syndrome drug therapy
- Published
- 2005
- Full Text
- View/download PDF
30. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
- Author
-
Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, and Roots I
- Subjects
- Adolescent, Adult, Aged, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System genetics, Female, Genotype, Heterozygote, Homozygote, Humans, Male, Middle Aged, Retrospective Studies, Exons genetics, Genes, MDR genetics, Haplotypes genetics, Immunosuppressive Agents pharmacokinetics, Kidney Transplantation, Tacrolimus pharmacokinetics
- Abstract
Aim: This retrospective study investigated the influence of MDR1 haplotypes derived from the polymorphisms 2677G > T (exon 21) and 3435C > T (exon 26) on the pharmacokinetics of the immunosuppressant drug tacrolimus in 73 renal transplant patients., Methods: Based on both variants of SNPs 2677 and 3435, four different haplotypes and eight different genotypes were identified in the study sample. Tacrolimus trough concentrations (C(0)) were compared between different SNP variants and genotypes, as well as between carriers and noncarriers of each haplotype. Additionally, CYP3A5 genotype (6956G > A) was determined., Results: No significant differences were observed between groups. Differences in mean tacrolimus C(0) values between carriers and noncarriers of each haplotype ranged from -0.04 microg/litre (95% confidence interval: -0.53 to 0.60) to -23 microg/litre (-1.07 to 1.53). No association was found between CYP3A5*1/*3 genotype and tacrolimus Co concentractions., Conclusion: MDR1 haplotypes derived from the SNPs 2677G > T (exon 21) and 3435C > T (exon 26) do not influence the pharmacokinetics of tacrolimus in renal transplant patients.
- Published
- 2004
- Full Text
- View/download PDF
31. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.
- Author
-
Filler G and Lepage N
- Subjects
- Child, Humans, Drug Monitoring, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents therapeutic use, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid pharmacokinetics, Mycophenolic Acid therapeutic use
- Abstract
Within a short period, we have witnessed a dramatic increase in the use of mycophenolate mofetil (MMF) in pediatric renal transplantation, with the drug often replacing azathioprine in combination with calcineurin inhibitor therapy. When the drug was introduced, the manufacturer considered therapeutic drug monitoring (TDM) unnecessary. However, TDM studies revealed substantial inter- and intra-individual variability and drug interactions. There is a substantial drug interaction between MMF and cyclosporine, and lower doses are required in combination with tacrolimus (~500-800 mg/m(2) per day) than with cyclosporine (~1,200 mg/m(2) per day). Patients with autoimmune disease require an intermediate dose when receiving no concomitant calcineurin inhibitor (~900 mg/m(2) per day). It has been possible to detect drug interactions and to minimize adverse events only with TDM. This is especially important with increasing use of combination therapies. Pharmacodynamic monitoring (measuring the biological response to a drug) coupled with pharmacokinetics allow optimization of drug dosing, with maximum efficacy and minimal toxicity. More work is required to establish specific target ranges with the various drug combinations--especially for the pediatric population.
- Published
- 2004
- Full Text
- View/download PDF
32. Drug interactions between mycophenolate and cyclosporine.
- Author
-
Filler G
- Subjects
- Area Under Curve, Child, Cyclosporine administration & dosage, Drug Interactions, Drug Therapy, Combination, Humans, Immunosuppressive Agents administration & dosage, Kidney Transplantation, Mycophenolic Acid administration & dosage, Mycophenolic Acid pharmacokinetics, Cyclosporine pharmacokinetics, Immunosuppressive Agents pharmacokinetics, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid pharmacology
- Published
- 2004
- Full Text
- View/download PDF
33. Treatment of nephrotic syndrome in children and controlled trials.
- Author
-
Filler G
- Subjects
- Child, Humans, Randomized Controlled Trials as Topic, Adrenal Cortex Hormones administration & dosage, Alkylating Agents administration & dosage, Cyclosporine administration & dosage, Immunosuppressive Agents administration & dosage, Nephrosis, Lipoid drug therapy, Nephrotic Syndrome drug therapy
- Abstract
Aim: To determine the sequential therapy of childhood nephrotic syndrome (NS) with presumed minimal change nephropathy using the evidence from clinical trials., Methods: Meta-analysis of 22 randomized controlled trials was performed, using frequency of relapse and side effects of therapeutic regimes., Results: A meta-analysis of seven trials comparing duration of therapy for initial onset showed that duration of at least 3 months significantly reduced the risk of relapse at 12-24 months (relative risk 0.73; 95% confidence interval 0.60-0.89) without an increase in adverse events. Five trials were performed for steroid treatment of relapse. Deflazacort reduced relapses during therapy, but is not generally available. No difference was observed when comparing single and divided dosing of prednisone. Frequency of relapses could not be influenced by duration of relapse therapy. Alternate day therapy was more effective than intermittent use of prednisone. Two studies out of five on cyclophosphamide or chlorambucil showed consistently that alkylating agents should be used before cyclosporine as alternative therapy to steroids., Conclusions: Children with initial onset of NS should be treated with prednisone at a dose of 60 mg/m(2)/day for 6 weeks, followed by a dose of 40 mg/m(2)/48 h for at least another 6 weeks. If steroid toxicity for treatment of relapsing NS requires alternative treatment, cyclophosphamide (2 mg/kg/day for at least 8 weeks) remains the drug of choice with a curative potential. If children still relapse after alkylating agents, levamisole may serve as an alternative only for frequent relapsing NS, whereas steroid-dependent NS should be treated with cyclosporine.
- Published
- 2003
- Full Text
- View/download PDF
34. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children.
- Author
-
Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I, and Feber J
- Subjects
- Adolescent, Anti-Glomerular Basement Membrane Disease drug therapy, Antiphospholipid Syndrome drug therapy, Child, Female, Granulomatosis with Polyangiitis drug therapy, Humans, Immunosuppressive Agents administration & dosage, Lupus Erythematosus, Systemic drug therapy, Male, Mycophenolic Acid administration & dosage, Nephritis, Interstitial drug therapy, Remission Induction, Treatment Outcome, Autoimmune Diseases drug therapy, Immunosuppressive Agents pharmacokinetics, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid pharmacokinetics
- Abstract
This study describes the pharmacokinetics of mycophenolate mofetil (MMF) in 15 pediatric patients with vasculitis and connective tissue disease involving the kidney. Patients included 10 with systemic lupus erythematosus (SLE), 1 with antiphospholipid antibody syndrome, 2 with Wegener granulomatosis, and 1 each with Goodpasture syndrome, Henoch-Schönlein-associated nephritis, and 1 with severe tubulointerstitial nephritis and uveitis. All patients were treated with steroids and additional therapy prior to treatment with MMF, which was administered for a median of 491 days. Mean starting dose of MMF was 974+/-282 mg/m(2 )in two divided doses. Pharmacokinetic monitoring of the active compound of MMF, mycophenolic acid (MPA), was performed using an EMIT assay. The mean MPA AUC after a median of 39 days was 61.8+/-31.0 micro gxh/ml, median time to maximum concentration was 60 min, and mean maximum concentration was 18.5+/-8.4 micro g/ml. At last follow-up, mean MMF dose was 900+/-341 mg/m(2) per day, and mean trough MPA concentration was 3.1+/-1.1 (range 0.6-4.6) micro g/ml. Therapy was effective in inducing remission in 4 of 9 patients with active disease. Only 1 of the 5 other patients relapsed. All 6 patients with controlled disease maintained remission. There were few side effects: one episode each of diarrhea and leukocytopenia and two viral infections. We conclude that MMF at 900 mg/m(2) per day appears to be effective in these patients.
- Published
- 2003
- Full Text
- View/download PDF
35. Cyclosporin A monitoring and AUC determination--where do we go?
- Author
-
Filler G
- Subjects
- Humans, Pediatrics, Area Under Curve, Cyclosporine pharmacokinetics, Immunosuppressive Agents pharmacokinetics
- Published
- 2002
- Full Text
- View/download PDF
36. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.
- Author
-
Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes D, Ehrich JH, Klare B, Zacchello G, Bjorn Brekke I, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, and Stolpe J
- Subjects
- Acute Disease, Adolescent, Child, Female, Follow-Up Studies, Graft Rejection, Graft Survival, Humans, Male, Prospective Studies, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use, Kidney Transplantation, Tacrolimus therapeutic use
- Abstract
This study was undertaken to compare the efficacy and safety of tacrolimus (Tac) with the microemulsion formulation of cyclosporin (CyA) in children undergoing renal transplantation. A 6-month, randomized, prospective, open, parallel group study with an open extension phase was conducted in 18 centers from nine European countries. In total, 196 pediatric patients (<18 years) were randomly assigned (1:1) to receive either Tac ( n=103) or CyA microemulsion ( n=93) administered concomitantly with azathioprine and corticosteroids. The primary endpoint was incidence and time to first acute rejection. Baseline characteristics were comparable between treatment groups. Tac therapy resulted in a significantly lower incidence of acute rejection (36.9%) compared with CyA therapy (59.1%) ( P=0.003). The incidence of corticosteroid-resistant rejection was also significantly lower in the Tac group compared with the CyA group (7.8% vs. 25.8%, P=0.001). The differences were also significant for biopsy-confirmed acute rejection (16.5% vs. 39.8%, P<0.001). At 1 year, patient survival was similar (96.1% vs. 96.6%), while 10 grafts were lost in the Tac group compared with 17 graft losses in the CyA group ( P=0.06). At 1 year, mean glomerular filtration rate (Schwartz estimate) was significantly higher in the Tac group (62+/-20 ml/min per 1.73 m(2), n=84) than in the CyA group (56+/-21 ml/min per 1.73 m(2), n=74, P=0.03). The most frequent adverse events during the first 6 months were hypertension (68.9% vs. 61.3%), hypomagnesemia (34.0% vs. 12.9%, P=0.001), and urinary tract infection (29.1% vs. 33.3%). Statistically significant differences ( P<0.05) were observed for diarrhea (13.6% vs. 3.2%), hypertrichosis (0.0% vs. 7.5%), flu syndrome (0.0% vs. 5.4%), and gum hyperplasia (0.0% vs. 5.4%). In previously non-diabetic children, the incidence of long-term (>30 days) insulin use was 3.0% (Tac) and 2.2% (CyA). Post-transplant lymphoproliferative disease was observed in 1 patient in the Tac group and 2 patients in the CyA group. In conclusion, Tac was significantly more effective than CyA microemulsion in preventing acute rejection after renal transplantation in a pediatric population. The overall safety profiles of the two regimens were comparable.
- Published
- 2002
- Full Text
- View/download PDF
37. Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease.
- Author
-
Filler, Guido, Sharma, Ajay Parkash, Levy, Deborah M., and Yasin, Abeer
- Subjects
- *
PHARMACOKINETICS , *PEDIATRIC therapy , *AUTOIMMUNE disease treatment , *MYCOPHENOLIC acid , *THERAPEUTIC equivalency in drugs , *DRUG dosage , *IMMUNOSUPPRESSIVE agents , *TRANSPLANTATION of organs, tissues, etc. in children , *ENTERIC-coated tablets - Abstract
Background: Therapy with mycophenolate mofetil (MMF) has become a valuable therapeutic option in children with autoimmune disease. MMF prescription in children with autoimmune diseases differs from that in transplant recipients in terms of different dosing regimen, and concomitant administration of other immunosuppressive medications. Recently, another formulation of the same active compound, mycophenolic acid (MPA), has become available as enteric-coated Mycophenolate Sodium (EC-MPS). Dosing and pharmacokinetics of EC-MPS in pediatric autoimmune disease have never been studied. Methods: We therefore performed a pilot study on 6 patients, who were treated with EC-MPS. All patients underwent 1-2 full 10-point pharmacokinetic (PK) profiles over a 12-hour dosing interval. We compared the results with that of 22 similar patients on MMF therapy. Results: Median EC-MPS dose was 724 mg/m² (range 179-933 mg/m²). The MPA Area-Under-The-(Time- Concentration)-Curves (AUCs) on MMF and EC-MPS were comparable (54.4 mg × h/L on MMF and 44.0 mg × h/L on EC-MPS, n.s., Mann Whitney). After correcting for bioequivalence, the dose-normalized AUCs were also similar on both the formulations. However, PK profiles on EC-MPS were quite random, and time to maximum concentration varied from 30 minutes to 720 minutes. The concentration at six-hour correlated best with the AUC. This was different from a homogenous PK-profile on MPA. Conclusions: EC-MPS has a different PK profile from MMF. The data suggest that patients on EC-MPS must undergo a complete PK profile to assess adequate exposure. The 6-hour concentration provides an estimate of the exposure and should be targeted between 3-4 mg/L. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
38. Influence of commonly used drugs on the accuracy of cystatin C-derived glomerular filtration rate.
- Author
-
Foster, Jennifer, Reisman, William, Lepage, Nathalie, and Filler, Guido
- Subjects
GLOMERULAR filtration rate ,KIDNEY diseases ,ANTIBIOTICS ,IMMUNOSUPPRESSIVE agents ,MEDICAL radiology ,PHARMACODYNAMICS - Abstract
There is controversy about the effect of certain drugs on cystatin C (CysC) concentrations, which would limit the usability of CysC for estimation of glomerular filtration rate (GFR) in patients with renal disease. Seventy-one children (ages 2.6 months to 18 years) with renal disease and on at least one study medication (tacrolimus, cyclosporine, mycophenolate mofetil, corticosteroids, fosinopril, ramipril and enalapril, losartan, cotrimoxazole) were tested in 85 nuclear medicine GFR clearance studies with simultaneous CysC determinations. We analyzed the relationship between the dose per kilogram and the ratio of the measured GFR to the CysC-derived GFR, with a ratio of 1 resembling agreement. A non-zero slope in linear regression analysis was considered significant for a drug effect on CysC. No significant relationship was found between the doses of the medication and the cystatin C GFR for any of the medications. Only cotrimoxazole showed a GFR ratio that was significantly lower than 1, which may be related to small numbers; otherwise the value was always 1. CysC provides accurate data for calculating GFR independent of the drug doses studied and avoids the use of methods of direct GFR measurement. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
39. Glomerular filtration rate as a putative ‘surrogate end-point’ for renal transplant clinical trials in children.
- Author
-
Filler, Guido, Browne, Richard, and Seikaly, Mouin G.
- Subjects
- *
HOMOGRAFTS , *IMMUNOSUPPRESSIVE agents , *CLINICAL trials - Abstract
Abstract: Only with prospective randomized controlled trials is it possible to evaluate the several immunosuppressive regimens available to renal allograft recipients. Commonly used surrogate markers of clinical outcome, such as patient and graft survival, are constantly improving. Current immunosuppressive protocols have improved 1-yr graft survival to over 90%. The small differences in graft survival among the various immunosuppressive regimes require large patient cohorts in order to establish statistical significance. Such studies are often difficult to conduct in a timely manner, particularly in children. This necessitates the search for better surrogate markers sensitive enough to detect differences in smaller cohorts and in a shorter period of time. While the degree of fibrosis in transplant biopsies might well predict long-term graft survival, protocol biopsies are expensive, invasive, and unpopular among clinicians. In native kidneys, glomerular filtration rate (GFR) closely correlates with disease progression and interstitial fibrosis and appears to be well positioned as a less invasive surrogate marker for long-term outcome. Nonetheless, the ideal marker for GFR remains obscure. Serum creatinine has several major drawbacks, making it a poor predictor of GFR. This review discusses the several methods used to estimate or measure GFR with emphasis on 125 I-iothalamate clearance and serum cystatin C (cys-C). Of all the serum markers, cys-C is the most reliable and the most promising. However, cys-C and other endogenous markers cannot replace the diagnostic sensitivity and reliability of radiolabeled markers of GFR such as 125 I-iothalamate in renal transplant clinical trials. Unfortunately, clearance of most radiolabeled markers of GFR including 125 I-iothalamate remain costly and time consuming. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
40. Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing.
- Author
-
Filler, Guido, Lathia, Anita, LeBlanc, Claire, and Christians, Uwe
- Subjects
- *
IMMUNOSUPPRESSIVE agents , *HEMODIALYSIS , *DRUG dosage , *DRUG metabolism , *LUPUS erythematosus , *SODIUM in the body , *PATIENTS - Abstract
Enteric-coated mycophenolate sodium (EC-MPS) has a mean half-life of 11.7 hours, which encouraged hope of using this drug once daily in a nonadherent adolescent SLE patient. This is a case report on a 17-year-old adolescent with a history of noncompliance who was switched from twice-daily mycophenolate mofetil (MMF) to once-daily EC-MPS. The EC-MPS dose was equimolar to the daily MMF dose (1 g MMF BID and 1.44 g of EC-MPS OD). The active compound of both drugs, mycophenolic acid, was measured using a commercially available EMIT assay. Both drugs were well-tolerated and maintained remission of the SLE. The average of three 12-hour areas under the time–concentration curves (AUC) on 1 g of MMF BID was 59.0 mg×h/L. In contrast, the 24-hour AUC after 1.44 g EC-MPS OD was 283.2 mg×h/L, more than double the expected 118.0 mg×h/L of two MMF dosing intervals. A repeat 24-hour AUC after 1.08 g of EC-MPS was 218.2 mg×h/L. EC-MPS once daily may be a well-tolerated therapeutic option for nonadherent adolescent lupus patients, but may be associated with a significantly higher exposure than the equivalent MMF BID dose. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.